Abstract: Provide are a diagnostically useful carrier coated with a recombinant polypeptide comprising SEQ ID NO: 1, an isolated autoantibody binding specifically to a polypeptide having SEQ ID NO: 1, a kit comprising the carrier, a method for the diagnosis of a membranous nephropathy (MN) that includes detecting the presence or absence of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 in a liquid sample comprising antibodies from a subject, a use of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 or a polypeptide comprising SEQ ID NO: 1, and a aqueous solution comprising an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1.

Abstract: Provide are a diagnostically useful carrier coated with a recombinant polypeptide comprising SEQ ID NO: 1, an isolated autoantibody binding specifically to a polypeptide having SEQ ID NO: 1, a kit comprising the carrier, a method for the diagnosis of a membranous nephropathy (MN) that includes detecting the presence or absence of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 in a liquid sample comprising antibodies from a subject, a use of an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1 or a polypeptide comprising SEQ ID NO: 1, and a aqueous solution comprising an autoantibody binding specifically to a polypeptide having SEQ ID NO: 1.

Abstract: The present invention relates to a method for diagnosing a disease, comprising the step detecting in a sample an autoantibody binding to the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, a use of a membrane-associated human Na(+)/K(+) ATPase or a variant thereof for the diagnosis of a disease, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase or a variant thereof, for use in the treatment of a disease, an autoantibody binding to said polypeptide and a method for isolating such autoantibody, a pharmaceutical composition, medical or diagnostic device or test kit comprising the polypeptide.

Abstract: A method for diagnosing a disease by detecting an autoantibody that binds to flotillin1 and/or flotillin2 in a sample, a polypeptide comprising flotillin1 and/or flotillin2 or a variant thereof, which may be immobilized, a method of treating a disease by applying to a subject the polypeptide that binds to an autoantibody, an autoantibody binding to flotillin1 and/or flotillin2, a method for isolating the autoantibody, a pharmaceutical composition, a medical device and test kit comprising the polypeptide, are provided. A method for detecting the presence of an autoantibody is also provided.

Abstract: Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.

Abstract: Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.

Abstract: A method for diagnosing a disease by detecting an autoantibody that binds to flotillin1 and/or flotillin2 in a sample, a polypeptide comprising flotillin1 and/or flotillin2 or a variant thereof, which may be immobilized, a method of treating a disease by applying to a subject the polypeptide that binds to an autoantibody, an autoantibody binding to flotillin1 and/or flotillin2, a method for isolating the autoantibody, a pharmaceutical composition, a medical device and test kit comprising the polypeptide, are provided. A method for detecting the presence of an autoantibody is also provided.

Abstract: Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.

Abstract: The present invention relates to a method for diagnosing a disease, comprising the step detecting in a sample an autoantibody binding to the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, a use of a membrane-associated human Na(+)/K(+) ATPase or a variant thereof for the diagnosis of a disease, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase or a variant thereof, for use in the treatment of a disease, an autoantibody binding to said polypeptide and a method for isolating such autoantibody, a pharmaceutical composition, medical or diagnostic device or test kit comprising the polypeptide.